Linzagolix
Linzagolix (INN; developmental code names KLH-2109, OBE-2109) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.[1][3][2] As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.[1]
Clinical data | |
---|---|
Other names | KLH-2109; OBE-2109 |
Routes of administration | By mouth[1][2] |
Drug class | GnRH modulator; GnRH antagonist; Antigonadotropin |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C22H15F3N2O7S |
Molar mass | 508.42 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
References
- "Linzagolix - Kissei Pharmaceutical/ObsEva - AdisInsight".
- Ezzati M, Carr BR (2015). "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain". Womens Health (Lond). 11 (1): 19–28. doi:10.2217/whe.14.68. PMID 25581052.
- Chodankar, Rohan; Allison, Jennifer (2018). "New Horizons in Fibroid Management". Current Obstetrics and Gynecology Reports. 7 (2): 106–115. doi:10.1007/s13669-018-0242-6. ISSN 2161-3303.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.